Mirdametinib in Histiocytic Disorders

• Status: Recruiting
• Trial end date: 2031-03-01

Summary

The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.

• Phase: Phase 2

Details

• Lead Sponsor: Children's Hospital Medical Center, Cincinnati